Joffe R T, Bakish D
Mood Disorders Program, Clarke Institute of Psychiatry, Toronto, Ontario, Canada.
J Clin Psychiatry. 1994 Jan;55(1):24-5.
To determine the efficacy and safety of a serotonin selective reuptake inhibitor (SSRI) combined with moclobemide in the treatment of 11 patients with various DSM-III-R diagnoses.
Subjects received moclobemide in doses of 150 to 800 mg/day together with sertraline (N = 5) in doses of 25 to 200 mg/day or fluvoxamine (N = 6) in doses of 50 to 200 mg/day. Patients were carefully monitored for side effects and for clinical response at the end of the trial, which lasted a minimum of 5 weeks.
The combination was tolerated extremely well. Insomnia was the most common side effect, occurring in 5 of 11 subjects. A marked or complete therapeutic response was noted in 8 of 11 subjects.
This open clinical trial suggests that combined SSRI-moclobemide treatment appears to be safe and well tolerated. It may also have therapeutic effects in treatment-refractory patients.
确定一种5-羟色胺选择性再摄取抑制剂（SSRI）联合吗氯贝胺治疗11例患有各种DSM-III-R诊断的患者的疗效和安全性。
受试者接受每日150至800毫克剂量的吗氯贝胺，同时接受每日25至200毫克剂量的舍曲林（N = 5）或每日50至200毫克剂量的氟伏沙明（N = 6）。在持续至少5周的试验结束时，仔细监测患者的副作用和临床反应。
该联合用药耐受性非常好。失眠是最常见的副作用，11名受试者中有5人出现。11名受试者中有8人出现明显或完全的治疗反应。
这项开放性临床试验表明，SSRI-吗氯贝胺联合治疗似乎安全且耐受性良好。它对难治性患者可能也有治疗效果。
